For many people living with diabetes or prediabetes, the daily routine of managing blood sugar is defined by needles and finger pricks. However, at CES 2026 , a health tech company is presenting a significant update on its quest to change that. One year after showing off the original concept, PreEvnt is now moving its non-invasive glucose alert system, called isaac, into human clinical trials.
The device represents a departure from traditional monitoring. Instead of measuring blood through the skin, isaac focuses on what is in a person’s breath.
Monitoring glucose via breath: isaac by PreEvnt advances
Isaac’s technology is based on being able to sense volatile organic compounds (VOCs). When blood sugar levels go up, the body makes certain biomarkers, like acetone, and then breathes them out. The wearable device has patented sensors that can find these compounds in a person’s breath and link them to changes in glucose levels.
Currently, the system is undergoing clinical trials at Indiana University Indianapolis. Researchers are testing how well the breath-based sensors perform compared to traditional blood-sampling methods. The study began with adolescents who have Type 1 diabetes and is now expanding to include adults with Type 2. These real-world data points are a critical requirement for the FDA pre-submission pathway that PreEvnt is currently navigating.
An integrated ecosystem
A wearable sensor is only as useful as the data it provides. So, the team has spent the last year refining the coordinating app for iOS, Android, and Apple Watch. The goal is to move away from “raw data” and toward actionable insights.
The app keeps track of patterns over time and can make reports that users can send to their doctors. It has an alert system, which is probably the most important thing for safety. If the device sees a big jump in glucose biomarkers, it can send a message to both the user and their emergency contacts. It is meant to give families and caregivers peace of mind without the hassle of having to do constant invasive tests.
Who is it for?
It is important to note that isaac is being positioned as a “glucose alert system.” In other words, it is not a direct replacement for medical-grade continuous glucose monitors (CGMs) used for insulin dosing. The primary target audience includes individuals with type 2 diabetes who are not on insulin, people with prediabetes, and those generally interested in metabolic health.
By providing a non-invasive way to spot trends, the device aims to help users make better lifestyle and dietary choices before their glucose levels become a serious issue. It serves as an early warning system that fits into a daily routine as easily as a smartwatch.
The path to market
Even though there is a lot of excitement about non-invasive monitoring, isaac is still a work in progress. The device is still being looked at by regulators, so it isn’t available for sale in the U.S. yet. Clinical trials are proving that the app works, and the app ecosystem is almost done. PreEvnt wants to launch its product in the second half of 2026.
If PreEvnt ‘s project successfully clears the final engineering and FDA hurdles, it could represent a major shift in how millions of people interact with their own metabolic data—replacing the needle with a simple breath.
